Neurocrine biosciences presents new data analyses demonstrating efficacy of fda-approved once-daily ongentys in patients with parkinson's disease

Neurocrine biosciences presents new data analyses demonstrating efficacy of fda-approved once-daily ongentys® (opicapone) in patients with parkinson's disease at the mds virtual congress 2020.neurocrine biosciences - ongentys 50 mg significantly reduced "off" time by more than an hour compared to placebo when used as an add-on treatment.
NBIX Ratings Summary
NBIX Quant Ranking